Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 4/2001

01.04.2001 | Adis New Drug Profile

Argatroban

verfasst von: Kate McKeage, Greg L. Plosker

Erschienen in: Drugs | Ausgabe 4/2001

Einloggen, um Zugang zu erhalten

Abstract

  • ▴ Argatroban is a direct thrombin inhibitor synthesised to bind to the catalytic site of the thrombin molecule. It binds rapidly and reversibly to both clot-bound and soluble thrombin.
  • ▴ The relatively short elimination half-life of argatroban (39 to 51 minutes) and its reversible binding allow rapid achievement of therapeutic effect on initiation of therapy and rapid restoration of normal haemostasis upon cessation of therapy.
  • ▴ Argatroban produces a predictable dose response that is well correlated with changes in anticoagulant parameters.
  • ▴ Argatroban, given to patients with heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia with thrombosis (HITTS) in a large scale, nonrandomised, prospective trial, reduced a combined end-point of morbidity and mortality when compared with historical controls.
  • ▴ Argatroban was well tolerated in clinical trials of patients with HIT and caused no increase in bleeding risk compared with historical controls.
Literatur
1.
Amiral J. Antigens involved in heparin-induced thrombocytopenia. Semin Hematol 1999; 36(1) Suppl. 1: 7–11PubMed
2.
Warkentin TE. Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management. Drug Saf 1997 Nov; 17(5): 325–41
3.
Kelton JG. The clinical management of heparin-induced thrombocytopenia. Semin Hematol 1999 Jan; 36(1) Suppl. 1: 17–21PubMed
4.
Alving BM, Krishnamurti C. Recognition and management of heparin-induced thrombocytopenia (HIT) and thrombosis. Semin Thromb Hemost 1997; 23(6): 569–74PubMedCrossRef
5.
AbuRahma AF, Boland JP, Wisberger T. Diagnostic and therapeutic strategies of white clot syndrome [abstract]. Am JSurg 1991 Aug; 162(2): 175–9CrossRef
6.
Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20(3): 318–29PubMedCrossRef
7.
Walenga JM, Ahmad S, Hoppensteadt DA, et al. Prolonged argatroban treatment does not result in the generation of neutralizing antibodies [abstract]. XVIIth Congress of the International Society on Thrombosis and Haemostasis; 1999 Aug 14
8.
John JP, Rozenfeld V. Focus on argatroban. PT 2000; 25(2): 70–2+77
9.
Hursting MJ, Alford KL, Becker JC, et al. Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin Thromb Hemost 1997; 23(6): 503–16PubMedCrossRef
10.
Bush LR. Argatroban, a selective, potent thrombin inhibitor. Cardiovasc Drug Rev 1991; 9(3): 247–63CrossRef
11.
Hijikata-Okunomiya A, Okamoto S. A strategy for a rational approach to designing synthetic selective inhibitors. Semin Thromb Hemost 1992; 18(1): 135–49PubMedCrossRef
12.
Berry CN, Girardot C, Lecoffre C, et al. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 1994; 72(3): 381–6PubMed
13.
Hantgan RR, Jerome WG, Hursting MJ. No effect of clot age or thrombolysis on argatroban’s inhibition of thrombin. Blood 1998 Sep 15; 92(6): 2064–74PubMed
14.
Swan SK, St Peter JV, Lambrecht LJ, et al. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000; 20(7): 756–70PubMedCrossRef
15.
Bergougnan L, Moore N, Brohier S, et al. Pharmacodynamic and pharmacokinetic profile of argatroban (1mg.ml−1 alcohol solution) in healthy man [abstract no.602]. J Clin Pharmacol 1998; 38: 878
16.
Lewis BE, Iqbal O, Hoppensteadt D, et al. Clinical pharmacokinetic and pharmacodynamic studies on argatroban to optimize the anticoagulant dosage in interventional cardiovascular procedures [abstract no. PS-2010]. Thromb Haemost 1997 Jun; Suppl.: 492
17.
Ahmad S, Ahsan A, Iqbal O, et al. Pharmacokinetics and pharmacodynamics of argatroban as studied by HPLC and functional methods: implications in the monitoring and dosageoptimizations in cardiovascular patients. Clinical and Applied Thrombosis/Hemostasis 1998; 4(4): 243–9CrossRef
18.
Ueki Y, Matsumoto K, Kizaki Y, et al. Argatroban increases nitric oxide levels in patients with peripheral arterial obstructive disease: placebo controlled study. J Thromb Thrombolysis 1999; 8: 131–7PubMedCrossRef
19.
Winn MJ, Jain K, Ku DD. Argatroban and inhibition of the vasomotor actions of thrombin. J Cardiovasc Pharmacol 1993; 22(5): 754–60PubMedCrossRef
20.
Hijikata-Okunomiya A, Nakaya Y, Inoue N, et al. Effects of argatroban on thrombin-induced events in cultured vascular smooth muscle cells. Thromb Res 2000 Feb 15; 97: 257–62PubMedCrossRef
21.
GlaxoSmithKline. Comments re argatroban antcoagulant therapy in patients with heparin induced thrombocytopenia. (Data on file 2001)
22.
Tatsuno J, Komatsu T, Iida S. Pharmacokinetic studies of argipidine (MD-805) -Protein binding and blood cell bindingfin Japanese]. Jpn Pharmacol Ther 1986; 14 Suppl. 5: 243–9
23.
Ahmad S, Ahsan A, George M, et al. Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: potential clinical applications. Clin Applied Thromb/ Hemost 1999; 5(4): 252–8CrossRef
24.
Izawa O, Katsuki M, Komatsu T, et al. Pharmacokinetic studies of argipidine (MD-805) in human — concentrations of argipidine and its metabolites in plasma, urine and feces during and after drip intravenous infusion [in Japanese]. Jpn Pharmacol Ther 1986; 14 Suppl. 5: 251–63
25.
Tran JQ, DiCicco RA, Sheth SB, et al. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol 1999; 39: 513–9PubMed
26.
Inglis AL, Sheth SB, Hursting MJ, et al. Lack of interaction between argatroban, a direct thrombin inhibitor, and 3 frequently prescribed medications, acetaminophen, lidocaine and digoxin [abstract no. P-488E]. ASHP 35th Mid-Year Clinical Meeting; Dec; Las Vegas
27.
Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. In press
28.
Lewis BE, Walenga JM, Wallis DE. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost 1997; 23(2): 197–202PubMedCrossRef
29.
Lewis BE, Cohen M, Leya F, et al. Argatroban use in patients with heparin-induced thrombocytopenia during percutaneous coronary intervention. Chest 2000 Oct; 118(4) Suppl.: 261S
30.
Lewis B, Cohen M, Moses J, et al. Argatroban anticoagulation during initial and repeat percutaneous coronary intervention (PCI) in patients with heparin-induced thrombocytopenia (HIT) [abstract no. TCT-32]. Am J Cardiol 2000 Oct 16; 86 Suppl. 8A: 14i
31.
Lewis BE, Matthai W, Grassman ED, et al. Results of phase 2/3 trial of argatroban anticoagulation during PTCA of patients with heparin-induced thrombocytopenia (HIT) [abstract no. 1199]. Circulation 1997 Oct21; 96(8) Suppl.: 217
32.
Lewis BE, Rangel Y, Fareed J. The first report of successful carotid stent implant using argatroban anticoagulation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome: a case report. Angiology 1998 Jan; 49(1): 61–7PubMedCrossRef
33.
Lewis BE, Grassman ED, Wrona L, et al. Novastan anticoagulation during renal stent implant in a patient with heparininduced thrombocytopenia. Blood Coagul Fibrinolysis 1997; 8: 54–8PubMedCrossRef
34.
Matsuo T, Yamada T, Yamanashi T, et al. Anticoagulant therapy with MD805 of a hemodialysis patient with heparin-in-duced thrombocytopenia. Thromb Res 1990 Jun 15; 58: 663–6PubMedCrossRef
35.
Matsuo T, Chikahira Y, Yamada T, et al. Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on heparin induced thrombocytopenia during hemodialysis. Thromb Res 1988 Oct 15; 52: 165–71PubMedCrossRef
36.
SmithKline Beecham Pharmaceuticals. Argatroban prescribing information. Philadelphia, US, Aug 2000
Metadaten
Titel
Argatroban
verfasst von
Kate McKeage
Greg L. Plosker
Publikationsdatum
01.04.2001
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 4/2001
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200161040-00005

Weitere Artikel der Ausgabe 4/2001

Drugs 4/2001 Zur Ausgabe

Adis New Drug Profile

Argatroban

Adis New Drug Profile

Argatroban

Therapy in Practice

Managing Cancer-Related Anorexia/Cachexia

Leading Article

Potential of Microvascular Reperfusion with Adjunctive Pharmacological Intervention

Adis Drug Evaluation

Linezolid

Review Article

Review of Macrolides and Ketolides